Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge

Dogwood Therapeutics

13/08/2026 13:39

Overview
US biopharmaceutical developer reported no Q2 revenue and net loss widened yr/yr
Q2 net loss increased due to $6.7 mln non-cash impairment charge
Cash on hand of $9.6 mln provides runway through Phase 2b readout in Q4 2026

Outlook
Dogwood expects top-line results from Halneuron Phase 2b trial in fall 2026
Company has begun Phase 2b long-term extension study for Halneuron in CINP
SP16 study to begin enrolling in second half of 2026 for chemotherapy-induced pain

Result Drivers
INCREASED R&D SPENDING - Higher research and development expenses mainly driven by increased costs for Halneuron Phase 2b CINP study
NON-CASH IMPAIRMENT CHARGE - $6.7 mln net non-cash impairment charge related to goodwill and IPR&D recognized due to decline in market capitalization
HIGHER ADMINISTRATIVE COSTS - General and administrative expenses rose due to increased salaries, personnel costs and franchise fees

Company press release: ID:nGNXbd3Rdr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.34
 
Q2 Net Loss
 
$11.50 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $13.50, about 601.3% above its August 12 closing price of $1.93

Reuters Recommended Reads
Aug 13 - Grace Therapeutics Q1 net loss widens on impairment charges
Aug 13 - Cabaletta Bio Q2 net loss widens as R&D costs rise
Aug 12 - CNS Pharmaceuticals Q2 net loss widens, cash rises after financing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)